Erratum to: Effects of probiotic supplements on insulin resistance in gestational diabetes mellitus: A double-blind randomized controlled trial (Journal of Diabetes Investigation, (2019), 10, 1, (163-170), 10.1111/jdi.12863);Effects of probiotic supplements on insulin resistance in gestational diabetes mellitus: A double-blind randomized controlled trial

Journal of Diabetes Investigation

Volumn 10, Issue 1, 2019, Pages 163-170

  Kijmanawat, Athasit ^a   Panburana, Panyu ^a   Reutrakul, Sirimon ^a,b   Tangshewinsirikul, Chayada ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Gestational diabetes mellitus; Insulin resistance; Probiotics

Indexed keywords

GLUCOSE; INFLORAN; INSULIN; PLACEBO; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIFIDOBACTERIUM BIFIDUM; BODY WEIGHT CHANGE; BODY WEIGHT GAIN; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LACTOBACILLUS ACIDOPHILUS; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; NUTRITIONAL COUNSELING; PATIENT COMPLIANCE; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECOND TRIMESTER PREGNANCY; THAILAND; THIRD TRIMESTER PREGNANCY; TREATMENT DURATION; TREATMENT OUTCOME; BLOOD; DIET THERAPY; DIETARY SUPPLEMENT; GESTATIONAL AGE; PREGNANCY;

ADULT; BLOOD GLUCOSE; DIABETES, GESTATIONAL; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; GESTATIONAL AGE; HUMANS; INSULIN; INSULIN RESISTANCE; PREGNANCY; PROBIOTICS; TREATMENT OUTCOME;

EID: 85059499806     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.13109     Document Type: Erratum

References (43)

1. Sacks DA, Hadden DR, Maresh M, et al. Frequency of gestational diabetes mellitus at collaborating centers based on IADPSG consensus panel-recommended criteria: the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. Diabetes Care 2012; 35: 526–528.
2. Yogev Y, Xenakis EM, Langer O. The association between preeclampsia and the severity of gestational diabetes: the impact of glycemic control. Am J Obstet Gynecol 2004; 191: 1655–1660.
3. Ehrenberg HM, Durnwald CP, Catalano P, et al. The influence of obesity and diabetes on the risk of cesarean delivery. Am J Obstet Gynecol 2004; 191: 969–974.
4. Metzger BE, Lowe LP, Dyer AR, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008; 358: 1991–2002.
5. Crowther CA, Hiller JE, Moss JR, et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005; 352: 2477–2486.
6. Hartling L, Dryden DM, Guthrie A, et al. Benefits and harms of treating gestational diabetes mellitus: a systematic review and meta-analysis for the U.S. Preventive Services Task Force and the National Institutes of Health Office of Medical Applications of Research. Ann Intern Med 2013; 159: 123–129.
7. Meshel S, Schejter E, Harel T, et al. Can we predict the need for pharmacological treatment according to demographic and clinical characteristics in gestational diabetes? J Matern Fetal Neonat Med 2016; 29: 2062–2066.
8. Reid G. Food and Agricultural Organization of the, United Nation and the WHO. The importance of guidelines in the development and application of probiotics. Curr Pharm Des 2005; 11: 11–16.
9. Dugoua JJ, Machado M, Zhu X, et al. Probiotic safety in pregnancy: a systematic review and meta-analysis of randomized controlled trials of Lactobacillus, Bifidobacterium, and Saccharomyces spp. J Obstet Gynaecol 2009; 31: 542–552.
10. Didari T, Solki S, Mozaffari S, et al. A systematic review of the safety of probiotics. Expert Opin Drug Saf 2014; 13: 227–239.
11. Cao L, Wang L, Yang L, et al. Long-term effect of early-life supplementation with probiotics on preventing atopic dermatitis: a meta-analysis. J Dermatolog Treat 2015; 26: 537–540.
12. Sullivan A, Nord CE. The place of probiotics in human intestinal infections. Int J Antimicrob Agents 2002; 20: 313–319.
13. Saez-Lara MJ, Gomez-Llorente C, Plaza-Diaz J, et al. The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials. Biomed Res Int 2015; 2015: 505878.
14. Ganji-Arjenaki M, Rafieian-Kopaei M. Probiotics are a good choice in remission of inflammatory bowel diseases: a meta analysis and systematic review. J Cell Physiol 2017; 233: 2091–2103.
15. Palacios T, Vitetta L, Coulson S, et al. The effect of a novel probiotic on metabolic biomarkers in adults with prediabetes and recently diagnosed type 2 diabetes mellitus: study protocol for a randomized controlled trial. Trials 2017; 18: 7.
16. Li C, Li X, Han H, et al. Effect of probiotics on metabolic profiles in type 2 diabetes mellitus: a meta-analysis of randomized, controlled trials. Medicine 2016; 95: e4088.
17. Laitinen K, Poussa T, Isolauri E. Probiotics and dietary counselling contribute to glucose regulation during and after pregnancy: a randomised controlled trial. Br J Nutr 2009; 101: 1679–1687.
18. Dolatkhah N, Hajifaraji M, Abbasalizadeh F, et al. Is there a value for probiotic supplements in gestational diabetes mellitus? A randomized clinical trial. J Health Popul Nutr 2015; 33: 25.
19. Lindsay KL, Brennan L, Kennelly MA, et al. Impact of probiotics in women with gestational diabetes mellitus on metabolic health: a randomized controlled trial. Am J Obstet Gynecol 2015; 212: 496.e1–496.e11.
20. Karamali M, Dadkhah F, Sadrkhanlou M, et al. Effects of probiotic supplementation on glycaemic control and lipid profiles in gestational diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Metab 2016; 42: 234–241.
21. Jafarnejad S, Saremi S, Jafarnejad F, et al. Effects of a multispecies probiotic mixture on glycemic control and inflammatory status in women with gestational diabetes: a randomized controlled clinical trial. J Nutr Metab 2016; 2016: 5190846.
22. Wickens KL, Barthow CA, Murphy R, et al. Early pregnancy probiotic supplementation with Lactobacillus rhamnosus HN001 may reduce the prevalence of gestational diabetes mellitus: a randomised controlled trial. Br J Nutr 2017; 117: 804–813.
23. Badehnoosh B, Karamali M, Zarrati M, et al. The effects of probiotic supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in gestational diabetes. J Matern Fetal Neonatal Med 2017; 10: 1–9.
24. Lee YK, Conway P, Pettersson S, et al. ILSI Southeast Asia Region conference proceedings: the gut, its microbes and health: relevance for Asia. Asia Pac J Clin Nutr 2017; 26: 957–971.
25. Jandhyala SM, Talukdar R, Subramanyam C, et al. Role of the normal gut microbiota. World J Gastroenterol 2015; 21: 8787–8803.
26. Voreades N, Kozil A, Weir TL. Diet and the development of the human intestinal microbiome. Front Microbiol 2014; 5: 494.
27. Metzger BE, Gabbe SG, Persson B, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010; 33: 676–682.
28. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487–1495.
29. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.
30. Taylor BL, Woodfall GE, Sheedy KE, et al. Effect of probiotics on metabolic outcomes in pregnant women with gestational diabetes: a systematic review and meta-analysis of randomized controlled trials. Nutrients 2017; 9: 461.
31. Paszti-Gere E, Szeker K, Csibrik-Nemeth E, et al. Metabolites of Lactobacillus plantarum 2142 prevent oxidative stress-induced overexpression of proinflammatory cytokines in IPEC-J2 cell line. Inflammation 2012; 35: 1487–1499.
32. Yadav H, Lee JH, Lloyd J, et al. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem 2013; 288: 25088–25097.
33. Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, et al. Probiotic yogurt improves antioxidant status in type 2 diabetic patients. Nutrition 2012; 28: 539–543.
34. Kim YA, Keogh JB, Clifton PM. Probiotics, prebiotics, synbiotics and insulin sensitivity. Nutr Res Rev 2017; 17: 1–17.
35. Gomes AC, Bueno AA, de Souza RG, et al. Gut microbiota, probiotics and diabetes. Nutr J 2014; 13: 60.
36. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696–1705.
37. Backhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004; 101: 15718–15723.
38. Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol 1999; 277: E1–E10.
39. Boulange CL, Neves AL, Chilloux J, et al. Impact of the gut microbiota on inflammation, obesity, and metabolic disease. Genome Med 2016; 8: 42.
40. Dumas ME, Barton RH, Toye A, et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci USA 2006; 103: 12511–12516.
41. Catalano PM, McIntyre HD, Cruickshank JK, et al. The hyperglycemia and adverse pregnancy outcome study: associations of GDM and obesity with pregnancy outcomes. Diabetes Care 2012; 35: 780–786.
42. Hoppu U, Isolauri E, Laakso P, et al. Probiotics and dietary counselling targeting maternal dietary fat intake modifies breast milk fatty acids and cytokines. Eur J Nutr 2012; 51: 211–219.
43. Luoto R, Kalliomaki M, Laitinen K, et al. The impact of perinatal probiotic intervention on the development of overweight and obesity: follow-up study from birth to 10 years. Int J Obes 2010; 34: 1531–1537.